Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply

JAMA Pediatr. 2018 Jul 1;172(7):701-702. doi: 10.1001/jamapediatrics.2018.0733.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Morals
  • Muscular Atrophy, Spinal*
  • Oligonucleotides*

Substances

  • Oligonucleotides
  • nusinersen